BioHarvest Sciences Inc. Common Stock BHST
Nov 4, 2026, 12:59 PM EST
- YTD
- -71.48%
- 1 year
- -82.83%
- Market cap
- 33.55M
- Revenue (ttm)
- 19.13M
- Profit margin
- -84.84%
- EPS (ttm)
- -0.51
- Shares out
- 17.33M
- YTD return
- -71.48%
- 1-year return
- -82.83%
- Volume
- 5.20K
- Avg volume
- 36.54K
- Open
- 1.53
- Previous close
- 1.54
- Day's range
- 1.47 – 1.53
- 52-week range
- 1.37 – 9.25
- Beta
- 1.49
- Analysts
- Buy
- Price target
- 14.67 (+891.0%)
2Y -3.28 (-68.33%)
Key statistics
- Enterprise value
- 114.38M
- PEG ratio
- 0.00
- Price / sales
- 5.53
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 119.20%
- Free cash flow
- -5.96M
- Total cash
- 5.17M
- Total debt
- 10.39M
- Return on equity
- -5955.96%
- Short % of float
- 0.00%
- 50-day average
- 5.70
- 200-day average
- 4.12
Analyst view
Consensus: buy
- Target (low)
- 12.00
- Target (mean)
- 14.67
- Target (high)
- 18.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 25, 2024 | Sep 1, 2024 | -0.05 | -0.16 | -0.11 | -220.00% |
About BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
- Country
- Canada
- Website
- bioharvest.com
News
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026 
BioHarvest takes second plant-cell asset to commercial readiness 
BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization 
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity 
BioHarvest says its platform can produce target sweetener in Tate & Lyle program 
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme 
BioHarvest Sciences launches buyback of up to 5% of shares 
BioHarvest Sciences Board Authorizes Normal Course Issuer Bid To Repurchase Up To 5% Of Outstanding Common Shares 
BioHarvest Sciences Announces Share Repurchase Program 
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
Your note
Sign in to keep a note on BHST — it syncs with the Stock Master app.